Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2023 - 2025)

Monte Rosa Therapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $112159.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 8.09% year-over-year to $112159.0; the TTM value through Dec 2025 reached $112159.0, down 8.09%, while the annual FY2025 figure was $112159.0, 8.09% down from the prior year.
  • Gains from Sales and Divestitures reached $112159.0 in Q4 2025 per GLUE's latest filing, roughly flat from $112159.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $122034.0 in Q3 2024 to a low of $4691.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 3 years is $70944.2, with a median of $65377.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 85.87% in 2024, then skyrocketed 1095.6% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $43600.0 in 2023, then soared by 179.89% to $122034.0 in 2024, then fell by 8.09% to $112159.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Gains from Sales and Divestitures are $112159.0 (Q4 2025), $112159.0 (Q3 2025), and $112159.0 (Q2 2025).